Invesco NASDAQ Biotech UCITS ETF Acc
Top 10 Exposures as of 14 Feb 2020 (%)
| Name | ISIN | Weight |
|---|---|---|
| GILEAD SCIENCES ORD | US3755581036 | 7.93% |
| AMGEN ORD | US0311621009 | 7.51% |
| VERTEX PHARMACEUTICALS ORD | US92532F1003 | 7.43% |
| BIOGEN ORD | US09062X1037 | 7.12% |
| ILLUMINA ORD | US4523271090 | 5.21% |
| REGENERON PHARMACEUTICALS ORD | US75886F1075 | 4.27% |
| ALEXION PHARMACEUTICALS ORD | US0153511094 | 2.73% |
| SEATTLE GENETICS ORD | US8125781026 | 2.43% |
| INCYTE ORD | US45337C1027 | 2.03% |
| BIOMARIN PHARMACEUTICAL ORD | US09061G1013 | 1.92% |
Key information
| Bloomberg ticker | SBIO LN |
| ISIN | IE00BQ70R696 |
| Benchmark BBG ticker | XNBI |
| Management fee | 0.40% |
| Swap fee | 0.00% |
| NAV (14 Feb 2020) | $39.14 |
| AUM | $506,661,653 |
| Base currency | USD |
Key documents
Key risks
Counterparty risk: Other financial institutions provide services such as safekeeping of assets or as a counterparty to financial contracts such as derivatives. The Fund is exposed to the risk of bankruptcy, or any other type of default of the counterparty related to any trading transaction entered into by the Fund.
Risk of using derivatives: in order to reach its investment objective, the Fund enters into swap agreements which provide the performance of the Reference Index, and may imply a range of risks which could lead to an adjustment or even the early termination of the swap agreement.
Liquidity on secondary market risk: Lower liquidity means there are insufficient buyers or sellers to allow the Fund to sell or buy investments readily. On-exchange liquidity may be limited due to Reference Index suspension, a decision by one of the relevant stock exchanges, or a breach by the market maker of respective stock exchange requirements and guidelines.
The performance information on this web page refers to past performance. Past performance is not a reliable indicator of future returns.
The data shown on this page is not real-time, i.e. it may be delayed due to mandatory requirements of the data provider. As a consequence, the price of the product linked to a specific underlying you are quoted by your broker or intermediary may substantially differ from the price of the product that you would expect on the basis of the data displayed on this site. Invesco accepts no responsibility for loss, however caused, resulting from errors in this data.
ETF performance is in the fund’s base currency, includes dividends, reinvested. ETF performance is Net Asset Value after management fees and other ETF costs but does not consider any commissions or custody fees payable when buying, holding or selling the ETF. The ETF does not charge entry or exit fees. Data: Invesco.